NCM·Healthcare·$348M·#320 / 520 in Healthcare
IRD Opus Genetics, Inc.
36HIGH RISK
CATEGORY BREAKDOWN
GROWTH47
QUALITY0
STABILITY67
VALUATION1
GOVERNANCE45
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+29.1%
47
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
15 months
54
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
7.4%
94
< 25% strong
Price / Sales
Market cap relative to trailing revenue
29.0x
1
< 3x strong
Rule of 40
Growth rate plus operating margin
-243
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
11.1%
67
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+37.8%
0
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE IRD WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when IRD's score changes by 5+ points.
DATA INFO
Last updated: Jul 1, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.